Release time：2023-10-12
On the afternoon of August 18, 2022, Director Lu Meiyao of Huatai United Securities visited the company to discuss the company's product application scenarios, future production and sales planning and financing needs with Chairman Guan Guoliang and General Manager Chen Qiaoling.
At the symposium, General Manager Chen Qiaoling introduced the company's project - POCT rapid gene screening platform technology based on LAMP-BIOSENSOR-AI to Director Lu and his entourage, and introduced in detail the advanced research results, product competitive advantages and strategic planning. Director Lu Meiyao made detailed inquiries about the company's projects, expressed strong interest in the company's products in the field of medical testing, and was also optimistic about the market prospects of the company's products in non-medical fields (such as pet testing and animal epidemic prevention). The two sides had in-depth discussions and exchanges on matching resources, and will continue to pay attention to and follow up the progress of the company's projects.
After the meeting, General Manager Chen Qiaoling led Director Lu and his entourage to visit the company, and demonstrated the operation process of the company's self-developed POCT automatic portable genetic detection analyzer, which let investors understand the advantages of the company's products of speed, precision, miniaturization, automation, low cost and high throughput through an intuitive way.
